XML 50 R19.htm IDEA: XBRL DOCUMENT
v3.25.3

FAIR VALUE MEASUREMENTS | 12 Months Ended
--- | ---
Jul. 31, 2025
Fair Value Disclosures [Abstract] |
FAIR VALUE MEASUREMENTS | NOTE 8: FAIR VALUE MEASUREMENTS The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of July 31, 2025 and 2024: SCHEDULE OF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE ON A RECURRING BASIS
|  | Fair Value Measurements at |
|  | July 31, 2025 |  |  | July 31, 2024 |
|  | Level 1 |  |  | Level 2 |  |  | Total |  |  | Level 1 |  |  | Level 2 |  |  | Total |
Financial Assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 10,493,808 |  |  | $ | - |  |  | $ | 10,493,808 |  |  | $ | 862,089 |  |  | $ | - |  |  | $ | 862,089 |
Short-term investments |  |  | 7,372,473 |  |  |  | - |  |  |  | 7,372,473 |  |  |  | - |  |  |  | - |  |  |  | - |
Total assets measured at fair value |  | $ | 17,866,281 |  |  | $ | - |  |  | $ | 17,866,281 |  |  | $ | 862,089 |  |  | $ | - |  |  | $ | 862,089 |
Financial liabilities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants liability |  | $ | 151,586 |  |  | $ | 186,086 |  |  | $ | 337,672 |  |  | $ | 760,657 |  |  | $ | 335,379 |  |  | $ | 1,096,036 |
Total liabilities measured at fair value |  | $ | 151,586 |  |  | $ | 186,086 |  |  | $ | 337,672 |  |  | $ | 760,657 |  |  | $ | 335,379 |  |  | $ | 1,096,036 |
The Company classifies its cash equivalents, short-term investments and the liability in respect of publicly traded warrants within Level 1 because they are valued using the quoted market prices in active markets. The Company holds level 1 short term investments with coupon rates ranging between 3.00% to 5.51% The fair value of the warrant liability for non-public warrants is measured using inputs other than quoted prices included in Level 1 that are observable for the liability either directly or indirectly, and thus are classified as Level 2 financial instruments. BriaCell Therapeutics Corp Notes to the Consolidated Financial Statements For the Years Ended July 31, 2025 and 2024 (Expressed in US Dollars, except share and per share data and unless otherwise indicated)

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/820/tableOfContent + Details
Name: | us-gaap_FairValueMeasurementInputsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration